Dermatologic Adverse Events in Pediatric Patients Receiving Targeted Anticancer Therapies: A Pooled Analysis

The document analyzed dermatologic adverse events (AEs) in pediatric patients receiving targeted anticancer therapies across 19 clinical trials involving 955 patients. Common AEs included rash (19%), xerosis (18%), mucositis (17%), and pruritus (7%), with hair disorders such as trichomegaly and alopecia also noted. The study emphasized the significant morbidity associated with these AEs and the need for pediatric oncologists to recognize and manage these conditions to avoid unnecessary dose modifications or therapy discontinuation, thereby maintaining patients' quality of life. The inclusion of dermatologists in the care team and personalized pre-therapy counseling were recommended to improve clinical outcomes.